Bioregulators & Organ Support
Vilon
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Immunity Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 20 mg
Dosing window: Anytime
Receptor / target: Thymus
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg daily | Standard Khavinson protocol. Repeat every 6 months. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1: 5-Day Monthly Cycle Gradual Titration (Goal: sustained year-round immune maintenance; first-time users or subjects sensitive to immune activation)
| Timeframe | Dose | Notes |
|---|---|---|
| Month 1, Day 1 | 67 mcg 1x Daily | Gradual ramp: introduce thymopoietic signaling slowly to minimize first-cycle immune activation symptoms. |
| Month 1, Day 2 | 133 mcg 1x Daily | |
| Month 1, Day 3 | 200 mcg 1x Daily | |
| Month 1, Day 4 | 267 mcg 1x Daily | |
| Month 1, Day 5 | 333 mcg 1x Daily | |
| Month 2+, Day 1 | 333 mcg 1x Daily | Continue escalation each month until reaching 600 mcg cap. |
| Month 2+, Day 2 | 400 mcg 1x Daily | |
| Month 2+, Day 3 | 467 mcg 1x Daily | |
| Month 2+, Day 4 | 533 mcg 1x Daily | |
| Month 2+, Day 5 | 600 mcg 1x Daily |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: 10-Day Quarterly Cycle (Goal: general immunosenescence reversal and aging immune normalization on a quarterly schedule)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 5mg 1x Daily | Half-dose intensive. Repeat every 3 months. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3: Pre-Vaccination Immune Priming (Goal: maximize vaccine immunogenicity in aging or immunosenescent subjects by restoring naive T-cell output before antigen exposure)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (4 weeks before vaccination) | 10mg 1x Daily | Full standard course 4 weeks before scheduled vaccination. Goal is to restore naive T-cell output and T-cell receptor repertoire breadth before novel antigen exposure. |
| Days 1-5 (1 week post-vaccination) | 5mg 1x Daily | Follow-up half-dose course to support the expanding antigen-specific T-cell response during the consolidation window. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 4: Post-Chemotherapy Immune Reconstruction (Goal: rebuild thymopoiesis and naive T-cell output following chemotherapy-induced lymphopenia; minimum 4 weeks post-chemotherapy, ANC > 1.0)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 1mg 1x Daily | Ultra-conservative entry. Bone marrow recovery must be confirmed (ANC > 1.0) before initiating. Requires medical supervision. |
| Weeks 3-4 | 2mg 1x Daily | |
| Weeks 5-8 | 5mg 1x Daily | |
| Weeks 9-12 | 10mg 1x Daily | Full standard dose once T-cell recovery markers are trending toward normal range. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 5: Longevity Stack Integration with Epithalon + Crystagen (Goal: biannual deep immunosenescence reversal as part of comprehensive Khavinson anti-aging protocol)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg 1x Daily | Run concurrently with Epithalon 10-day course. Stagger Crystagen to begin on Day 11 to avoid peak immune activation overlap. |
| Days 11-20 | 5mg 1x Daily | Vilon taper phase. Crystagen begins at its standard dose on Day 11. Provides sequential thymopoiesis restoration (Vilon) followed by broad peripheral immune normalization (Crystagen). |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (Thymus); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Organ transplant recipients on immunosuppressive therapy: Vilon's T-cell restoration and thymopoietic stimulation directly counteracts the immunosuppressive regimens (calcineurin inhibitors, mTOR inhibitors, corticosteroids) required to prevent allograft rejection; restored T-cell activity increases the risk of acute and chronic rejection; absolute contraindication. Limited / unverified
- Active autoimmune disease in acute flare: the immune normalization activity of Vilon, while not non-specific immunostimulation, could exacerbate the T-cell-mediated pathology driving active autoimmune flares in conditions such as rheumatoid arthritis, lupus, multiple sclerosis, or inflammatory bowel disease; use during active flare requires medical supervision. Limited / unverified
- Concurrent immunosuppressive therapy for non-transplant indications (high-dose corticosteroids, methotrexate, azathioprine, biologic immunosuppressants): Vilon's immunoregulatory activity works against the therapeutic intent of these medications. Limited / unverified
- Known hypersensitivity to Vilon (Lys-Glu dipeptide) or formulation excipients. Limited / unverified
- Active hematological malignancies involving T-cell lineages (T-cell lymphoma, T-cell leukemia): Vilon's thymopoietic stimulation in the context of malignant T-cell clonal expansion could theoretically support tumor cell proliferation. Limited / unverified
- Pregnancy: immune regulation changes substantially during pregnancy; exogenous thymic bioregulator activity during gestation is not characterized. Limited / unverified
- Pediatric use in subjects with intact thymic function: the thymus is highly active in children and young adults; Vilon's therapeutic target (the involuted aging thymus) does not exist in young subjects and the effects of superimposed thymic bioregulator stimulation on normally functioning thymopoiesis are not established. Limited / unverified
Side effects (limited evidence)
- Transient immune activation symptoms: as T-cell output normalizes and immune competence is restored, some subjects experience mild flu-like symptoms (low-grade fatigue, mild myalgia) in the first days of a new cycle; reflects immune system reactivation rather than infection or adverse response. Limited / unverified
- Mild injection site reaction: standard subcutaneous dipeptide injection response; minimal due to the small molecular size of Vilon. Limited / unverified
- Transient mood changes: the neuroimmune cross-regulation between the thymus and the CNS/HPA axis means thymic bioregulator activity can produce subtle mood shifts in some subjects during the active cycle; typically mild and transient. Limited / unverified
- Potential worsening of subclinical autoimmune conditions: immune normalization in subjects with undiagnosed autoimmune predisposition could unmask or mildly exacerbate previously subclinical autoimmune processes as immune surveillance and T-cell reactivity are restored. Limited / unverified
- No serious adverse events documented in the Khavinson research literature: the 40+ year Russian clinical use history of Vilon at standard protocol doses has not produced documented serious adverse events; the safety profile is considered excellent in the eligible (aging, immunosenescent, non-transplant, non-active-autoimmune) population. Limited / unverified
- Unknown interaction profile with modern biologic immunomodulatory drugs: Vilon's research predates the modern biologic immunotherapy era; interactions with checkpoint inhibitors, monoclonal antibodies, and targeted immunomodulators are not characterized. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.